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ABSTRACT 
Background: HSV-1 epidemiology in the Middle East and North Africa (MENA) remains 
poorly understood. Our study aimed to measure HSV-1 antibody prevalence (seroprevalence) 
and its age-distribution among select MENA populations residing in Qatar. 
Methods: Sera were collected from male blood donors attending Hamad Medical Corporation 
2013-2015. A total of 2,077 sera were tested for anti-HSV-1 antibodies using HerpeSelect® 1 
ELISA IgG kits (Focus Diagnostics, USA). Robust Poisson regression was conducted to estimate 
adjusted infection prevalence ratios. 
Results: Country-specific HSV-1 seroprevalence was estimated for 10 national populations: 
97.5% among Egyptians, 92.6% among Yemenis, 90.7% among Sudanese, 88.5% among 
Syrians, 86.5% among Jordanians, 82.3% among Qataris, 81.4% among Iranians, 81.4% among 
Lebanese, 80.5% among Palestinians, and 77.0% among Pakistanis. Age-specific HSV-1 
seroprevalence was estimated for Egypt, the Fertile Crescent (Iraq, Jordan, Lebanon, Palestine, 
and Syria), and Qatar. Seroprevalence increased with age among Fertile Crescent and Qatari 
nationals. Seroprevalence increased from 70.0% among those aged ≤24 years up to 98.0% 
among those aged ≥55 years among Fertile Crescent nationals. Seroprevalence was consistently 
above 90% for all ages among Egyptians.  
Conclusions: HSV-1 seroprevalence is high in MENA, though with some variation across 
countries. The seroprevalence appears to have declined among current young age cohorts 
compared to its levels a few decades ago. This article is protected by copyright. All rights reserved 
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INTRODUCTION 
Herpes simplex virus type 1 (HSV-1) infection is endemic globally and is the primary cause of 
orolabial herpes.1-4 HSV-1 is highly infectious, with most infections occurring during 
childhood.1,5 Following initial acquisition, the virus introduces latency in nerve cell clusters 
causing an infection that persists for life.3,6 HSV-1 is commonly transmitted by non-sexual 
contact (primarily through oral secretions), with most infections showing no apparent 
symptoms.3,7,8 When symptomatic, infection is often characterized by oral or facial lesions, that 
is at the initial portal of entry.6,7 HSV-1 infection is associated with oral, cutaneous, ocular, and 
central nervous system manifestations, and thus infection can lead to mild to serious or severe 
morbidity, such as gingivostomatitis, herpes labialis, herpetic whitlow, neonatal herpes, corneal 
blindness, meningitis, and encephalitis.6,9  
HSV-1 can also be transmitted to susceptible persons through oral sex or sexual intercourse 
resulting in genital herpes, given the genital portal of initial entry.3,7,10 Recent evidence from 
Western countries indicates a growing role for HSV-1 as a sexually transmitted infection (STI) 
and a leading, if not the leading, cause of genital herpes.7,11-15  
With continued improvement in hygiene and living conditions, HSV-1 antibody prevalence 
(seroprevalence) appears to be declining at least in Western countries.1,5,16-22 HSV-1 
seroprevalence has declined by about 30% over the last three decades among adolescents 14-19 
years of age in the United States.8 Evidence suggests that a striking transition in HSV-1 
epidemiology, from an oral to increasingly genital infection, is already taking place in Western 
countries,7,8,23 and is resulting in significant clinical and psychosocial morbidity.4,7,23-25  
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In context of limited data on HSV-1 seroprevalence in MENA,1 the aim of our study was to 
assess HSV-1 seroprevalence among select MENA national populations and to characterize the 
infection’s age-distribution. Specifically, we assessed HSV-1 seroprevalence among male blood 
donors, from 11 MENA nationalities, who are currently residing in Qatar. Qatar is a MENA 
country situated in the Arabian Peninsula with a population of 2.2 million in 2014.26 Qataris 
constitute only 12% of the total population, with the vast majority of the population being recent 
short-term expatriate residents coming for contractual employment for specific number of 
years.26  
With a large fraction of these expatriates coming from other MENA countries, Qatar provided an 
opportune setting for a comparative study of HSV-1 seroprevalence among different MENA 
populations. HSV-1 seroprevalence among these expatriates should be comparable to HSV-1 
seroprevalence in their home countries. These expatriates are predominantly recent short-term 
residents in Qatar and spent most of their lifetime in their home countries—their seroprevalence 
should be more representative of the exposure risk in their home countries, rather than in Qatar. 
HSV-1 seroprevalence among men should also be representative of that among women, as 
existing global evidence suggests no major sex-specific differences.1,2 Since HSV-1 is mainly 
transmitted orally with a general-population epidemiology, we would further expect that the 
seroprevalence among blood donors should be comparable to that in the wider population, as 
supported also by existing evidence.1  
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MATERIALS AND METHODS 
Study design and participants 
This was an opportunistic cross-sectional study on volunteer blood donors from different MENA 
nationalities attending Hamad Medical Corporation, the main healthcare provider in Qatar, 
between June 2013 and June 2016. Blood donation in Qatar is a common practice, and 
individuals from diverse socioeconomic strata participate in blood donation campaigns. A total 
of 5,973 blood donors consented to provide blood specimens and basic demographic information 
including nationality, age, and sex. No identifiable information was collected. The blood 
specimens were collected for other studies,27-30 but remaining specimens were used for this 
study. The research work was approved by the ethics boards and research committees at Qatar 
University, Hamad Medical Corporation, and Weill Cornell Medicine-Qatar.  
The sample comprised Qataris and expatriates (MENA and non-MENA nationals) residing in 
Qatar, men and women, and adults ≥18 years of age. The sample included 5,799 men and 152 
women, with gender missing for 22 subjects. The number of female participants was small and 
consequently women were excluded. All specimens from non-MENA male nationals (n = 1,295) 
were also excluded. An additional MENA specimen (n = 1) was omitted due to missing gender 
information. The remaining 4,525 MENA specimens served as the original sampling cohort for 
selection of the final sample.  
Final sample sizes were calculated for a significance level of α = 0.05. Sample size of 50 was 
estimated for each five-year age group in each country to assess an age-specific HSV-1 
seroprevalence of 88% with a 10% precision level. Sample size of 200 was estimated for each 
country to assess the country’s overall HSV-1 seroprevalence of 88% with a 5% precision level. 
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The 88% seroprevalence was based on observed HSV-1 seroprevalence in a study from Saudi 
Arabia,31 also a MENA country.  
For estimating HSV-1 age-specific seroprevalence, a random sample of 50 subjects per age 
group was selected for each of Egypt, the Fertile Crescent (Iraq, Jordan, Lebanon, Palestine, and 
Syria), and Qatar (Table I). If serum was not sufficient for a subject, a replacement subject was 
randomly chosen with the same nationality and age group. There were not always sufficient 
subjects or serum to conduct the serology to reach the 50 target sample size per age category. 
Due to insufficient sample size in each country individually, the neighboring countries of Iraq, 
Jordan, Lebanon, Palestine, and Syria were merged together as one national unit, the Fertile 
Crescent, as they share similar socio-economic and socio-cultural attributes. No sufficient 
sample size was available to assess the age-specific seroprevalence in other countries.  
For estimating country-specific HSV-1 seroprevalence in countries where we did not have 
sufficient sample size to estimate the age-specific seroprevalence, a random sample of 200 
subjects was selected for each of Jordan, Pakistan, Palestine, and Syria. For Iran, Lebanon, 
Sudan, and Yemen, all available specimens were included in the study sample, as <200 were 
available for each of these countries (Table I). For countries with <100 subjects, no country-
specific estimate was conducted (Algeria, Iraq, Morocco, Oman, and Tunisia).  
Biological sample collection and laboratory analysis 
A portion of sera (50 µL) was aliquoted from existing sera samples that were stored at -80°C 
until used for serology testing. Sera were tested for the presence of anti-HSV-1 IgG using 
HerpeSelect® 1 enzyme linked immunosorbent assay (ELISA) kits (Cat. No. EL0910G-5, Focus 
Diagnostics, USA). This kit was designed for qualitative detection of type-specific IgG 
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antibodies to HSV-1 in human serum using a 96-microwell polystyrene plate coated with a 
purified recombinant HSV-1 glycoprotein-G antigen (gG1). The kit was approved for laboratory 
diagnosis of anti-HSV-1 IgG by the United States Food and Drug Administration.32  
Analysis and results were interpreted according to the manufacturer’s instructions: sera with 
optical density index values (cut-off) <0.90 were considered negative, values >1.10 were 
considered positive, and values ranging between 0.90 and 1.10 were considered equivocal.32 All 
equivocal specimens were retested. Those that remained equivocal were reported as equivocal.  
Data analysis  
Data was analyzed using the Statistical Package for the Social Sciences (SPSS) version 24. Age 
was categorized into eight five-year bands: ≤24, 25-29, 30-34, 35-39, 40-44, 45-49, 50-54, and 
≥55. Cross-tabulation between age and HSV-1 serostatus was performed for Egypt, the Fertile 
Crescent, and Qatar to describe the age-specific HSV-1 seroprevalence of the study population. 
Trends were assessed using the Cochran–Armitage test for trend. Robust Poisson regression 33 
was conducted to estimate the crude and adjusted effects of age and nationality on HSV-1 
seroprevalence. Significance level was defined at α = 0.05. 
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RESULTS 
In total, 2,077 serum specimens from subjects from 11 MENA countries were tested for HSV-1 
antibodies (Table I). The median age among those tested was 37 years. Serological testing 
identified 1,796 sera as positive, 280 as negative, and one as equivocal.   
The country-specific overall HSV-1 seroprevalence among men was estimated for 10 MENA 
national populations. The highest seroprevalence was among Egyptians at 97.5% (95% CI 95.3-
98.7%), and the lowest among Pakistanis at 77.0% (95% CI 70.7-82.3%). Seroprevalence for all 
national populations is presented in Table II.  
The age-specific HSV-1 seroprevalence was estimated for Egyptians, nationals of the Fertile 
Crescent (Iraq, Jordan, Lebanon, Palestine and Syria), and Qataris (Table III). Among Egyptians, 
HSV-1 seroprevalence was >90% in all age groups, with no evidence for growing or declining 
trend with age (p-value for trend = 0.259). Among Fertile Crescent nationals, HSV-1 
seroprevalence increased steadily with age starting from 70.0% (95% CI 56.3-80.9%) among 
those aged ≤24 years up to 98.0% (95% CI 89.5-99.7%) among those aged ≥55 years (p-value < 
0.001). Among Qataris, HSV-1 seroprevalence also increased with age (p-value < 0.001), and 
was lowest at 62.0% (95% CI 48.2-74.1%) among those aged 25-29 years.  
Both age and nationality were found to be associated factors with HSV-1 infection in both 
univariable and multivariable analyses (Table IV). There was a significant positive association 
between seroprevalence and age in the univariable analysis. Compared to those aged ≤24 years, 
all older age groups had higher seroprevalence. The crude prevalence ratios (PRs) increased from 
1.11 (95% CI 1.00-1.22) for those aged 25-29 years to 1.32 (95% CI 1.21-1.44) for those aged 
≥55 years. 
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There were also significant differences in seroprevalence with nationality in the univariable 
analysis. The crude prevalence ratios were significantly higher among Jordanians (PR = 1.12; 
95% CI 1.02-1.23), Syrians (PR = 1.15, 95% CI 1.05-1.26), Sudanese (PR = 1.18, 95% CI 1.07-
1.29), Yemenis (PR = 1.20, 95% CI 1.10-1.31), and Egyptians (PR = 1.27, 95% CI 1.17-1.37), 
compared to Pakistanis.  
Age and nationality remained significantly associated with seroprevalence in the multivariable 
analysis (Table IV). However, the prevalence ratio for Jordanians (PR = 1.08, 95% CI 0.98-1.15) 
was no longer significantly different compared to Pakistanis after age adjustment.  
 
DISCUSSION 
This is to our knowledge the most comprehensive HSV-1 seroprevalence study of different 
MENA populations and different age groups. We found that overall seroprevalence remains 
high, but for most nationalities, at lower levels than expected, based on earlier evidence and 
historical pattern.1,17,34-40 The seroprevalence decline appears to reflect lower seroprevalence 
among the younger age cohorts in recent time; as much as 30% of those <30 years of age have 
not been exposed to HSV-1. The high overall HSV-1 seroprevalence in MENA suggests that 
there may be significant HSV-1-related morbidity in the population at large that needs to be 
quantified and addressed including diseases such as gingivostomatitis, herpetic whitlow, corneal 
blindness, and encephalitis among others.6,9  
Our results indicated variation in HSV-1 seroprevalence across countries, and observed rates are 
consistent with the global evidence suggesting an association between HSV-1 infection and 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This article is protected by copyright. All rights reserved 
socio-economic status.1,8 Seroprevalence was higher in the lower-income countries of Egypt, 
Sudan, and Yemen, than in the relatively higher-income countries of Iran, Jordan, Lebanon, 
Palestine, Qatar, and Syria. A recent study from Saudi Arabia, a higher-income country, found 
also a seroprevalence similar to our results for the higher-income countries.31  
Pakistan though was a notable exception by being a lower seroprevalence (77%) and also a 
lower-income country. This finding remains to be confirmed and explained, but we are not aware 
of other comparable HSV-1 studies from Pakistan. Of note, however, HSV-1 seroprevalence in 
India, a neighboring country of Pakistan with similar socio-economic level, was reported to be at 
only 60%.2 These results may hint that the association between HSV-1 infection and socio-
economic status is more nuanced than previously thought.  
Our study has limitations. The specimens were only from male blood donors with no population- 
and probability-based sampling, exposing the study to potential selection bias. Specimens were 
collected from individuals of different nationalities, but all individuals were residing in Qatar at 
that time. HSV-1 seroprevalence among these expatriates may not necessarily reflect the 
seroprevalence in their home countries. Very basic socio-demographic variables were collected, 
limiting our ability to assess relevant individual-level associations such as education, socio-
economic status, or specific socio-cultural practices. Two different methods were used to select 
the testing samples depending on primary purpose, overall versus age-specific seroprevalence. 
For the overall seroprevalence, we chose the specimens randomly among all specimens for that 
nationality. Meanwhile, for the age-specific seroprevalence, we chose a fixed number of 
specimens (also randomly) for each age group, and then determined the overall seroprevalence in 
this sample based on the number of positives in all age groups. There is evidence for variation in 
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the sensitivity and specificity of HSV-1 assays by population,32,41,42 thereby potentially also 
affecting the estimated seroprevalence levels.  
Despite these limitations, selection bias may be less of an issue for HSV-1, as it is predominantly 
transmitted orally with a general-population epidemiology. In these blood-donor samples, the 
bias will probably be towards older populations, given that the median age in MENA countries is 
most often <25 years of age.43 Our estimated seroprevalence could be higher than actual 
seroprevalence, and our findings are possibly conservative about the extent of seroprevalence 
decline among youth in recent time. Though all tested individuals were Qatar residents, 
expatriates are not permanent migrants in Qatar, typically stay for only few years, and the vast 
majority have moved to Qatar recently thanks to economic expansion over the last decade. The 
assay used in this study (Focus HerpeSelect®) is highly regarded, approved by the United States 
Food and Drug Administration, and is among the most commonly used herpes assays in the 
literature.32 Lastly, these limitations should be considered in light of the logistical challenges and 
prohibitive costs to conduct HSV-1 nationally-representative studies on probability-based 
samples, limitations in availability of HSV-1 epidemiologic data globally,8 and the present 
opportunity to conduct this large-scale study by country and age group on existing samples. This 
is the first time HSV-1 seroprevalence data will appear in the literature for several of the 
included countries. 
In conclusion, HSV-1 seroprevalence is high in MENA though with some variation across 
countries. The seroprevalence appears also to have declined in recent decades, possibly reflecting 
reduced exposure during childhood. These findings highlight the need for monitoring of trends in 
HSV-1 seroprevalence, and etiological surveillance of diagnosed genital herpes and HSV-1 
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related morbidities. These findings argue also for rapid development of prevention interventions 
to control HSV-1 infection transmission and to prevent the associated clinical disease burden.  
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TABLES 
Table I Stratification of samples by nationality 
 Original  
sample size  
N=4,525 
Studied  
sample size  
N=2,077 
Male populations with sample size ≥200* 
Egypt 1001 358# 
Jordan 367 200 
Pakistan 231 200 
Palestine 309 200 
Qatar 1130 400 
Syria 776 200 
Male populations with 100 ≤ sample size ≤ 200 
Iran 115 113$ 
Lebanon 118 118 
Sudan 132 129& 
Yemen 152 148& 
Other populations with sample size <100 
Iraq 43 11 
Other 151 0 
* Sample was randomly selected 
# Only 39 and 19 sera were available for age groups 50-54 and ≥ 55, respectively 
& Not enough serum for serology testing 
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Table II Estimates of HSV-1 country-specific seroprevalence among male blood donors 
currently residing in Qatar but from different Middle East and North African countries  
Country Sample 
size 
Seroprevalence  
N+, (%) 
Seroprevalence 
95% CI 
Egypt 358 349 (97.5) 95.3-98.7 
Iran 113* 92 (81.4) 73.3-87.5 
Jordan 200 173 (86.5) 81.0-90.5 
Lebanon 118 96 (81.4) 73.4-87.4 
Pakistan 200 154 (77.0) 70.7-82.3 
Palestine 200 161 (80.5) 74.2-85.2 
Qatar 400 329 (82.3) 78.2-85.7 
Sudan 129 117 (90.7) 84.5-94.6 
Syria 200 177 (88.5) 83.9-92.6 
Yemen 148 137 (92.6) 87.2-95.8 
* One final equivocal HSV-1 result 
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Table III Estimates of HSV-1 age-specific seroprevalence among male blood donors currently residing in Qatar but from Egypt, the 
Fertile Crescent (including Iraq, Jordan, Lebanon, Palestine, and Syria), and Qatar 
 Egypt Fertile Crescent Qatar 
Age group Sample 
size 
Seroprevalence  
N+, (%) 
Seroprevalence 
95% CI 
Sample 
size 
Seroprevalence  
N+, (%) 
Seroprevalence 
95% CI 
Sample 
size 
Seroprevalence  
N+, (%) 
Seroprevalence 
95% CI 
≤24 years 50 46 (92.0) 81.2-96.9 50 35 (70.0) 56.3-80.9 50 35 (70.0) 56.3-80.9 
25-29 years 50 50 (100.0) 92.9-100.0 50 36 (72.0) 58.3-82.5 50 31 (62.0) 48.2-74.1 
30-34 years 50 49 (98.0) 89.5-99.7 50 41 (82.0) 69.2-90.2 50 40 (80.0) 67.0-88.8 
35-39 years 50 49 (98.0) 89.5-99.7 50 42 (84.0) 71.5-91.7 50 41 (82.0) 69.2-90.2 
40-44 years 50 49 (98.0) 89.5-99.7 50 42 (84.0) 71.5-91.7 50 42 (84.0) 71.5-91.7 
45-49 years 50 50 (100.0) 92.9-100.0 50 47 (94.0) 83.8-97.9 50 48 (96.0) 86.5-98.9 
50-54 years 39 37 (94.9) 83.1-98.6 50 49 (98.0) 89.5-99.7 50 46 (92.0) 81.2-96.9 
≥55 years 19 19 (100.0) 83.2-100.0 50 49 (98.0) 89.5-99.7 50 46 (92.0) 81.2-96.9 
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Table IV Crude and adjusted prevalence ratios (95% confidence intervals) for HSV-1 
seroprevalence among 2,077 male blood donors currently residing in Qatar but from different 
Middle East and North African countries  
 Crude prevalence 
ratio (95% CI) 
Adjusted prevalence 
ratio* (95% CI) 
Age   
≤24 years Ref Ref 
25-29 years 1.11 (1.00-1.22)  1.10 (1.00-1.21) 
30-34 years 1.14 (1.04-1.25) 1.15 (1.05-1.26) 
35-39 years 1.22 (1.12-1.34) 1.24 (1.13-1.35) 
40-44 years 1.24 (1.13-1.35) 1.25 (1.14-1.36) 
45-49 years 1.29 (1.18-1.41) 1.30 (1.19-1.42) 
50-54 years 1.32 (1.22-1.44) 1.32 (1.22-1.44) 
≥55 years 1.32 (1.21-1.44) 1.35 (1.24-1.47) 
Nationality   
Pakistan Ref Ref 
Qatar 1.07 (0.98-1.17) 1.04 (0.95-1.15) 
Egypt 1.27 (1.17-1.37) 1.25 (1.16-1.35) 
Iran 1.08 (0.96-1.21) 1.06 (0.95-1.19) 
Jordan 1.12 (1.02-1.23) 1.08 (0.98-1.18) 
Lebanon 1.06 (0.94-1.19) 1.03 (0.92-1.15) 
Palestine 1.05 (0.94-1.16) 1.03 (0.93-1.13) 
Sudan 1.18 (1.07-1.29) 1.17 (1.07-1.28) 
Syria 1.15 (1.05-1.26) 1.15 (1.05-1.26) 
Yemen 1.20 (1.10-1.31) 1.21 (1.11-1.31) 
* Adjusted for nationality and age 
 
